Imexpharm (STC:IMP) Market Cap: ₫6,606,984 Mil (As of Jun. 26, 2026)


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫42,900.00
GF Value ₫51,706.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Market Cap?

Imexpharm STC:IMP -1.38% 98 Market Cap is ₫6,606,984 Mil as of Jun. 26, 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Imexpharm ranks better than 51.22% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Imexpharm's share price for the quarter that ended in Mar. 2026 was ₫54700. Imexpharm's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 154 Mil. Therefore, Imexpharm's market cap for the quarter that ended in Mar. 2026 was ₫8,424,292 Mil.

Imexpharm's quarterly market cap declined from Sep. 2025 (₫8,116,274 Mil) to Dec. 2025 (₫8,085,473 Mil) but then increased from Dec. 2025 (₫8,085,473 Mil) to Mar. 2026 (₫8,424,292 Mil).

Imexpharm's annual market cap increased from Dec. 2023 (₫3,962,257 Mil) to Dec. 2024 (₫7,238,423 Mil) and increased from Dec. 2024 (₫7,238,423 Mil) to Dec. 2025 (₫8,085,473 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Imexpharm's Enterprise Value for Today is ₫6,345,135 Mil.


Imexpharm  (STC:IMP) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Imexpharm Market Cap Related Terms


Imexpharm Market Cap Historical Data

* Premium members only.

The historical data trend for Imexpharm's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Market Cap Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,187,037.14 4,013,620.00 3,962,257.27 7,238,423.00 8,085,472.50

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,861,100.95 7,916,062.60 8,116,274.30 8,085,472.50 8,424,292.30

STC:IMP vs ZTS: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imexpharm Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Market Cap distribution charts can be found below:

* The bar in red indicates where Imexpharm's Market Cap falls into.


STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Imexpharm's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=₫52500*154.009
=₫8,085,473

Imexpharm's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=₫54700*154.009
=₫8,424,292

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of ₫6,606,984 Mil mean?
Imexpharm (STC:IMP) has a Market Cap of ₫6,606,984 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Imexpharm and its competitors. According to the industry distribution chart, Imexpharm ranks #499 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 48.8%.
Is Imexpharm's Market Cap too high?
Imexpharm's current Market Cap is ₫6,606,984 Mil. Based on the distribution chart, Imexpharm ranks #499 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #499 out of 1023 companies for Market Cap. This puts Imexpharm in the upper half of its industry. The industry median Market Cap is 205.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current Market Cap is ₫6,606,984 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,900.00 — trading 17% below its estimated fair value. The current Market Cap is ₫6,606,984 Mil. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Market Cap is ₫6,606,984 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,900.00 is trading 17% below its estimated GF Value™ of ₫51,706.57. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Market Cap: ₫6,606,984 Mil
  • GF Value™: ₫51,706.57 vs. price of ₫42,900.00 (17% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,900.00
Price
₫51,706.57
GF Value